# Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

Source: https://onco.cc/trials/nct06531291/  
OnCo record `nct06531291` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of serplulimab and surufatinib in gallbladder cancer and other biliary tract cancers, run by RenJi Hospital, not yet recruiting.

## Summary

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation is a phase 2 interventional study registered as NCT06531291 by RenJi Hospital, with a registry enrolment figure of 80 participants, started 2024-08-10 and due to reach its primary completion in 2027-08-09. Interventions recorded: Surufatinib, Serplulimab, standard chemotherapy. Conditions listed: ESCC, Biliary Tract Cancer, Gastric Cancer, Pancreas Cancer. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT06531291
- Phase: 2
- Setting: Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation: A Single-arm, Multi-cohort, Open-label, Single-center, Prospective, Exploratory Clinical Study
- Sponsor: RenJi Hospital
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06531291: https://clinicaltrials.gov/study/NCT06531291

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Serplulimab](https://onco.cc/drugs/serplulimab/), [Surufatinib](https://onco.cc/drugs/surufatinib/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct06531291.json